Kiniksa Pharmaceuticals (Uk), LTD.

Kiniksa Pharmaceuticals (UK), LTD. Kinikska Division, a foreign-owned biopharmaceutical company headquartered in London, supplies specialty injectable pharmaceuticals to the federal government as a prime contractor competing on full-and-open GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) vehicles with no set-aside designations. The vendor operates 100% as a prime contractor with no subcontracting footprint, focusing exclusively on pharmaceutical product delivery rather than services.

Kinikska's federal portfolio centers on Arcalyst (Rilonacept), a 220 milligram per vial injectable medication indicated for chronic inflammatory disorders including recurrent pericarditis and cryopyrin-associated periodic syndromes. Recent representative awards include a $220,229.15 delivery order from Veterans Integrated Service Network 20 (VISN 20) in December 2025 for bulk Arcalyst 220 mg vials with 2026 pricing; a $193,121.16 delivery order from VISN 20 in June 2025 for bulk and annual Arcalyst supply supporting both VA and Department of Justice Bureau of Prisons; and a $170,125.09 delivery order from VISN 20 in June 2023 for Rilonacept 220 mg/vial injections with performance in Seattle, Washington. Task order values typically range from fifteen thousand to two hundred twenty thousand dollars.

The vendor's customer concentration is heavily weighted toward Department of Veterans Affairs service networks. The Department of Veterans Affairs National Acquisition Center anchors the portfolio at $5.9 million combined potential value through a single-award Blanket Purchase Agreement effective through November 2026; VISN 20 accounts for eight awards valued at $1.2 million combined; VISN 12 holds six awards at $785 thousand; VISN 21 carries four awards at eighty thousand dollars; and VISN 5 holds four awards at $136 thousand. The Department of Justice Bureau of Prisons Federal Medical Center Carswell represents the second major customer with six awards totaling $269 thousand. Together, these six customer entities cover 97% of award count and 99% of combined potential value.

Kinikska holds two indefinite delivery vehicles under the GSA Pharmaceuticals and Drugs schedule. The $5.9 million single-award Blanket Purchase Agreement with the VA National Acquisition Center (effective November 10, 2021 through November 9, 2026) enables streamlined task order issuance across VA facilities. The $700,000 multiple-award Federal Supply Schedule contract with VISN 12 (effective November 1, 2021 through October 31, 2026) supports task orders distributed across VISNs 12, 20, 21, and the Bureau of Prisons facility. Twenty-six task orders totaling $7.6 million combined potential value have been placed under the Pharmaceuticals and Drugs parent vehicle.

Award activity accelerated in 2024 (ten awards) following minimal volume in 2022 and 2023 (four and three awards respectively), with four awards in 2026 year-to-date. Only two awards face ultimate completion within the next twenty-four months, with combined potential value of $254 thousand, creating minimal near-term recompete exposure. The vendor's combined potential value across all twenty-nine prime awards totals $8.3 million, of which $1.7 million (20%) has been obligated to date, reflecting the indefinite delivery nature of the vehicle structure. Place of performance spans Great Britain (primary manufacturing location) and multiple U.S. locations including Dublin, Ohio; Westworth Village, Texas; Seattle, Washington; and La Vergne, Tennessee, serving geographically dispersed VA medical facilities and federal correctional institutions.